GlassScriptPhysician profile
Neera Sinha
NPI 1750745766
$1,699.84
in general payments reported to CMS, 2019-2025
28 companies · $594 in 2025
The $594 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.54 · 2023: $418 · 2024: $643 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,640 · Education: $15.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.26 |
| Education | $15.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $221.09 | 2023-2025 | Ibsrela |
| Abbvie INC. | $197.30 | 2023-2025 | Linzess, Viberzi, Rinvoq |
| Novo Nordisk INC | $164.02 | 2025 | Wegovy |
| Gilead Sciences, INC. | $150.00 | 2024 | Epclusa |
| Glaxosmithkline, LLC. | $122.20 | 2025 | Arexvy |
| Pfizer INC. | $95.04 | 2023-2024 | |
| Medtronic, INC. | $86.27 | 2023 | Minimed 780g |
| Celgene Corporation | $77.44 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $70.53 | 2023-2025 | Entyvio |
| Amgen INC. | $68.12 | 2024 | Evenity, Prolia, Krystexxa |
| Genzyme Corporation | $52.63 | 2023-2024 | |
| Janssen Biotech, INC. | $40.65 | 2024-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $40.07 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $37.63 | 2024 | Sutab, Suflave |
| Lilly USA, LLC | $34.05 | 2024 | Taltz, Zepbound |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.34 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.52 | 2022-2023 | Xifaxan |
| Organon LLC | $23.74 | 2024 | |
| Madrigal Pharmaceuticals | $20.60 | 2025 | Rezdiffra |
| Resmed Corp | $16.72 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $16.59 | 2023 | Arcalyst |
| Sobi, INC | $16.27 | 2025 | |
| Ferring Pharmaceuticals INC. | $15.79 | 2023 | Rebyota |
| Biohaven Pharmaceutical Holding Company LTD. | $15.75 | 2022 | |
| Mannkind Corporation | $15.31 | 2024 | |
| Celltrion USA INC. | $15.04 | 2024 | Zymfentra |
| Vanda Pharmaceuticals INC. | $14.93 | 2025 | Fanapt |
| Boston Scientific Corporation | $14.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neera Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.